ACT Share Price

Open 242.60 Change Price %
High 242.60 1 Day 0.00 0.00
Low 242.60 1 Week -1.85 -0.76
Close 242.60 1 Month -8.50 -3.39
Volume 22 1 Year 85.60 54.52
52 Week High 266.90
52 Week Low 125.25
ACT Important Levels
Resistance 2 242.60
Resistance 1 242.60
Pivot 242.60
Support 1 242.60
Support 2 242.60
ETR Germany Most Active Stocks
DBK 15.62 -1.39%
DBK 15.62 -1.39%
DTE 15.57 -1.02%
DTE 15.57 -1.02%
DTE 15.57 -1.02%
DTE 15.57 -1.02%
DTE 15.57 -1.02%
CBK 10.33 -2.18%
CBK 10.33 -2.18%
EOAN 8.36 -1.18%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
CFC 0.81 22.73%
CFC 0.81 22.73%
5M71 39.00 13.70%
TLI 0.28 12.00%
TLI 0.28 12.00%
VT9 43.00 11.11%
R3Q 0.11 10.00%
HP3 3.60 8.11%
V3V 7.98 7.26%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
ARO 0.01 -50.00%
ARO 0.01 -50.00%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
SC2 12.50 -14.97%
N4G 5.58 -12.68%
ADV 6.54 -11.38%
More..

Actelion Ltd (ETR: ACT)

ACT Technical Analysis 2.5
As on 19th Jul 2017 ACT Share Price closed @ 242.60 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 200.77 & Strong Sell for SHORT-TERM with Stoploss of 254.51 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACT Target for July
1st Target up-side 254.77
2nd Target up-side 258.95
3rd Target up-side 263.13
1st Target down-side 242.83
2nd Target down-side 238.65
3rd Target down-side 234.47
ACT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.actelion.com
ACT Address
ACT
Gewerberstrasse 16
Allschwil, 4123
Switzerland
Phone: 41 61 565 65 65
Fax: 41 61 565 65 00
ACT Latest News
Interactive Technical Analysis Chart Actelion Ltd ( ACT ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Actelion Ltd
ACT Business Profile
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.